Novo Stock (NVO) Tumbles. Ozempic, Wegovy Maker Has New CEO, Cuts U.S. Outlook - Barron's
1. NOVO.B stock fell 21.39% after lowered U.S. sales guidance. 2. New CEO appointed amid declining growth expectations for Wegovy and Ozempic. 3. Sales growth for 2025 revised down to 8%-14% from 13%-21%. 4. Marketplace competition intensifies with more emerging weight-loss alternatives. 5. Company pursuing litigation against knockoff drugs impacting its market share.